InMed Pharmaceuticals Inc. (OTCMKTS:IMLFF – Get Free Report) traded down 3.6% during mid-day trading on Wednesday . The company traded as low as $4.77 and last traded at $4.79. 20,203 shares changed hands during trading, an increase of 78% from the average session volume of 11,369 shares. The stock had previously closed at $4.97.
InMed Pharmaceuticals Price Performance
The company has a 50-day moving average of $3.91 and a 200-day moving average of $1.52.
About InMed Pharmaceuticals
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain.
See Also
- Five stocks we like better than InMed Pharmaceuticals
- Best Stocks Under $10.00
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- What is the Nikkei 225 index?
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Market Cap Calculator: How to Calculate Market Cap
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
